Semaglutide pushes blood sugar from the prediabetic range back to normal in a striking majority of people who take it. In the STEP 10 trial, roughly four out of five participants with obesity and prediabetes reverted to normal blood sugar levels within a year on semaglutide 2.4 mg, compared with about one in seven on placebo. The drug’s effects extend well beyond glucose, though, touching cardiovascular risk, liver health, inflammation, and quality of life in ways that make it more than a simple blood-sugar intervention.
How Well Does Semaglutide Reverse Prediabetes
The clearest evidence comes from the STEP clinical trial program, a series of large, placebo-controlled phase 3 trials testing once-weekly subcutaneous semaglutide at 2.4 mg. In STEP 10, which specifically enrolled people with obesity and prediabetes, 81% of participants on semaglutide had normal blood sugar by week 52, compared with 14% on placebo.1The Lancet Diabetes & Endocrinology. Efficacy and safety of semaglutide 2·4 mg for weight management and glycaemic control in participants with obesity and prediabetes (STEP 10) That is a nearly sixfold difference, and the odds ratio of reverting to normal glucose was about 20 to 1 in favor of the drug.
Other STEP trials painted a similar picture among participants who happened to have prediabetes at enrollment, even though those trials were not designed specifically for that group. In STEP 1, about 84% of participants with baseline prediabetes reached normal blood sugar by week 68 on semaglutide versus roughly 48% on placebo. STEP 3, which paired semaglutide with intensive behavioral therapy, saw rates of about 90% versus 55%. And in STEP 4, which tested what happens when you continue semaglutide versus switch to placebo after an initial run-in period, the figures were approximately 90% versus 70%.2PubMed Central. Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program The consistency across trials is one of the more reassuring things about the data. It was not a single lucky result.
One nuance worth noting: the placebo groups were not sitting at zero. Even on placebo, a substantial portion of prediabetic participants drifted back to normal blood sugar, especially in trials that included intensive lifestyle counseling. That makes sense because prediabetes is not a permanent state for everyone. But semaglutide roughly doubled those rates in every trial, and in STEP 10, where the placebo group had a much lower baseline reversal rate, the drug’s advantage was enormous.
How Semaglutide Shifts Blood Sugar and Insulin Sensitivity
Semaglutide is a GLP-1 receptor agonist, meaning it mimics a hormone your gut naturally releases after eating. That hormone slows stomach emptying, reduces appetite, and tells the pancreas to release insulin when blood sugar rises. But the drug’s effects on prediabetes are not just about more insulin. A large part of the benefit appears to flow through weight loss and the metabolic improvements that follow.
A trial called HISTORI, which tested semaglutide in people taking antipsychotic medications who had prediabetes and obesity, separated some of these effects. Participants on semaglutide lost an average of about 9 kg, and that weight loss drove measurable improvements in insulin sensitivity and reductions in insulin resistance. Interestingly, the improvements in how well the pancreas’s insulin-producing cells function were modest and not statistically definitive in that trial.3PubMed Central. Semaglutide Effects on Insulin Sensitivity and β-Cell Function in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics That suggests the drug’s prediabetes benefit comes primarily from making the body respond better to the insulin it already produces, rather than forcing the pancreas to work harder. For people in the prediabetic range, whose pancreases are generally still functioning but whose tissues are increasingly deaf to insulin, that is exactly the kind of correction you would want.
What Happens When You Stop
This is the question that matters most for long-term planning. Prediabetes is a chronic metabolic state, and if the drug only holds blood sugar in check while you take it, you are looking at indefinite treatment rather than a cure.
The STEP 1 trial extension followed participants for about a year after treatment ended. The news was mixed. People who had been on semaglutide saw their HbA1c creep back up after stopping, and the increase was larger than what happened in the placebo group over the same period. However, the semaglutide group still maintained a small net improvement compared to placebo at the end of follow-up, and their HbA1c remained lower than it had been before treatment began.4PubMed Central. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension In practical terms, stopping the drug erased a large chunk of the benefit but not all of it.
The weight regain that follows discontinuation likely drives much of the blood sugar rebound, since the metabolic improvements are so tightly linked to weight loss. This does not necessarily mean everyone needs to stay on semaglutide forever, but it does mean that people who stop should have a robust plan in place. Whether that involves a transition to lifestyle changes, a lower-intensity medication, or periodic retreatment is something researchers are still working out.
How Semaglutide Compares to Metformin
Metformin has been the go-to pharmacological option for prediabetes for over two decades, partly because it is cheap, well-studied, and reasonably well tolerated. A large nationwide cohort study comparing GLP-1 receptor agonists (the drug class semaglutide belongs to) with metformin in drug-naïve patients found that GLP-1 agonists produced a greater reduction in HbA1c in both prediabetic and diabetic patients. For people with prediabetes, GLP-1 agonists were also much less likely to need additional glucose-lowering medication added on within a year.5PubMed Central. Comparing Glucagon-like peptide-1 receptor agonists versus metformin in drug-naive patients: A nationwide cohort study
There is a catch, though. The same study found that people with prediabetes prescribed a GLP-1 agonist were about 60% more likely to stop taking their medication than those prescribed metformin. That gap in adherence may reflect a combination of factors: GLP-1 agonists are injectable, more expensive, and come with more gastrointestinal side effects, all of which make it harder for some people to stick with treatment.6PubMed Central. Comparing Glucagon-like peptide-1 receptor agonists versus metformin in drug-naive patients: A nationwide cohort study A drug that works better on paper but that people are more likely to quit does not always win in practice. For many patients, the choice between the two will depend on how well they tolerate injections, whether their insurance covers semaglutide, and how aggressively they and their doctor want to pursue blood sugar normalization.
Side Effects and Staying on Treatment
Gastrointestinal complaints are the main issue. Across the STEP trials, nausea affected about 44% of people on semaglutide 2.4 mg versus 16% on placebo. Diarrhea, vomiting, and constipation were also roughly two to three times more common on the drug.7PubMed Central. Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss Those numbers sound alarming, but the context matters. The vast majority of these events were mild or moderate and transient. They clustered during and shortly after dose escalation, which is the period when the dose is being gradually increased to the target level. Only about 4% of semaglutide-treated participants stopped the drug permanently because of GI side effects.8PubMed Central. Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss
So while almost half of users feel queasy at some point, very few find it intolerable enough to quit. The standard prescribing approach, which starts at a low dose and ramps up over several months, is specifically designed to minimize this. If you are considering semaglutide for prediabetes, expect some stomach discomfort early on, but know that for most people it fades.
Heart Health Beyond Blood Sugar
One of the strongest arguments for semaglutide in the prediabetes population has nothing to do with glucose. The SELECT trial enrolled over 17,000 people with overweight or obesity and established cardiovascular disease but without diabetes. A primary cardiovascular event, meaning cardiovascular death, nonfatal heart attack, or nonfatal stroke, occurred in about 6.5% of the semaglutide group versus 8% in the placebo group over the study period, a 20% relative risk reduction.9PubMed. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes That trial did not specifically target prediabetes, but a large share of people with obesity and no diabetes diagnosis fall somewhere on the prediabetes spectrum, making the results highly relevant to this population.
Part of the cardiovascular benefit may stem from the drug’s effects on inflammation. Exploratory analyses across STEP 1, 2, and 3 found that semaglutide reduced C-reactive protein, a marker of systemic inflammation, to a similar degree in people with prediabetes and those with normal blood sugar.10PubMed Central. Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3) Chronic low-grade inflammation is one of the mechanisms by which prediabetes and obesity drive heart disease, so tamping it down is a meaningful secondary benefit even in people whose primary concern is blood sugar.
Effects on Liver Disease
Metabolic dysfunction-associated steatotic liver disease, commonly called fatty liver disease, overlaps heavily with prediabetes. Both conditions are driven by insulin resistance and excess body fat, and having one substantially increases the risk of developing the other. A large propensity-matched study of over 38,000 patients with fatty liver disease found that those treated with semaglutide had significantly better survival, lower cardiovascular risk, and less progression to advanced liver disease compared with matched controls who did not receive the drug. Triglycerides, LDL cholesterol, and HbA1c all improved in the semaglutide group.11PubMed Central. Semaglutide in MASLD Patients: Improved Survival and Liver Outcomes
For people with prediabetes who also have fatty liver, and that is a large proportion of them, semaglutide may be addressing two intertwined problems with one treatment. The liver benefits are not just a side effect of weight loss, either; GLP-1 receptor agonists appear to have direct effects on liver inflammation and fibrosis, though those mechanisms are still being mapped out in detail.
Cost, Access, and Prescribing Patterns
Even if semaglutide works well for prediabetes, whether you can actually get it prescribed and afford it is a separate question. A health-economic analysis modeled the cost-effectiveness of semaglutide 2.4 mg for people with obesity and prediabetes in England. The analysis estimated that semaglutide extended life expectancy by about 1.7 years and provided roughly one additional quality-adjusted life year at an added cost of about £19,400, putting the cost per quality-adjusted life year at around £17,500. At a willingness-to-pay threshold of £20,000, the analysis gave semaglutide a 90% chance of being cost-effective.12PubMed. The cost-effectiveness of subcutaneous semaglutide 2.4 mg in the management of people living with obesity and prediabetes in England That threshold is specific to the UK’s National Health Service, but the findings suggest that from a healthcare-system perspective, the drug may pay for itself through prevented diabetes cases and reduced cardiovascular events.
In the United States, the landscape is messier. GLP-1 agonist prescribing has surged, but an analysis of prescribing trends found that fewer than 9% of GLP-1 RA users received a diabetes or prediabetes diagnosis within 30 days of starting the drug.13The American Journal of Managed Care. Trends in Glucagon-Like Peptide 1 Receptor Agonist Prescribing Patterns That means the overwhelming majority of prescriptions are going to people without a documented glucose abnormality, presumably for weight management. Whether that crowding-out effect makes it harder for prediabetic patients to access the drug is a real concern, particularly during periods of supply shortage.
Insurance coverage for semaglutide in prediabetes varies widely. Some insurers cover it under an obesity indication if you meet BMI criteria; others require a diabetes diagnosis. If you have prediabetes and are interested in semaglutide, the pathway may involve getting formally diagnosed with obesity as the primary indication, with prediabetes as a secondary one. It is worth having that conversation with your prescriber explicitly rather than assuming coverage.
Semaglutide in Adolescents
Prediabetes among teenagers has risen alongside childhood obesity, and there is growing interest in whether GLP-1 agonists can help younger patients the way they help adults. A systematic review of GLP-1 receptor agonists in pediatric obesity and diabetes found that semaglutide 2.4 mg weekly produced the largest BMI reductions among adolescents with obesity, and that weight-reducing agents in this class improved insulin resistance and modestly lowered triglycerides.14Diabetes Research and Clinical Practice. GLP-1 receptor agonists in pediatric obesity and diabetes: a systematic review of efficacy, metabolic effects, and safety The evidence is thinner than in adults, and the long-term implications of putting a developing teenager on a drug that suppresses appetite and alters gut signaling are not fully understood. But for adolescents with severe obesity and worsening insulin resistance, the risk-benefit calculation is starting to tilt in favor of pharmacological intervention alongside lifestyle changes.
Most of the adolescent data focuses on obesity as the primary outcome rather than prediabetes reversal specifically. That is a gap. Researchers know the drug lowers BMI and improves insulin resistance in teenagers, but large trials measuring how many adolescents with prediabetes revert to normal glucose levels, similar to STEP 10 in adults, have not been published yet.
Quality of Life and Physical Function
Prediabetes by itself does not usually cause symptoms you can feel, but the obesity that accompanies it often does. Joint pain, fatigue, reduced mobility, and lower overall physical functioning are common complaints. A randomized trial of semaglutide in people with prediabetes, obesity, and schizophrenia found that the semaglutide group improved their physical quality-of-life scores by about 3.6 points on the SF-36 scale compared to placebo. Mental quality-of-life scores and psychiatric symptoms, however, did not change.15Endocrine Abstracts. Effect of semaglutide vs placebo on HbA1c, weight, mental health and SF-36: a randomized clinical trial in people with pre-diabetes, obesity and schizophrenia
That split between physical and mental improvements is worth sitting with. Weight loss and better metabolic health translate into feeling physically better, moving more easily, and having more energy. But the psychological dimensions of living with obesity and metabolic disease are more complex and do not automatically resolve when the scale moves. If you are considering semaglutide primarily because you hope it will improve your mood or mental health, the current evidence does not support that expectation. The physical gains, though, are real and meaningful to the people who experience them.
Combining Semaglutide With Other Treatments
The clinical trials tested semaglutide mostly as a standalone drug alongside lifestyle counseling, but real-world practice is messier. Some clinicians are combining semaglutide with low-dose metformin for patients with prediabetes, particularly when they want to layer complementary mechanisms. A published case report described a woman with obesity, prediabetes, and a chromosomal abnormality who was treated with once-weekly semaglutide plus metformin 500 mg daily. After five months, her HbA1c dropped by 0.3 percentage points and her markers of insulin sensitivity normalized.16PubMed Central. Semaglutide Plus Low-Dose Metformin Combination Therapy for the Treatment of Obesity and Prediabetes in a Woman with Partial Deletion of the X Chromosome Long Arm A single case report is not strong evidence for combination therapy as a general strategy, but it reflects what some providers are already doing in practice. Metformin is cheap, well tolerated for most people, and works through a different mechanism than semaglutide, so the logic of pairing them is reasonable even if the evidence base has not caught up with the clinical instinct yet.
The bigger unanswered question is whether combining semaglutide with structured lifestyle programs produces durably better outcomes than either approach alone. STEP 3 included intensive behavioral therapy alongside the drug and saw some of the highest reversal rates, near 90%, but the study was not designed to isolate how much the behavioral component added versus the drug alone. For people with prediabetes, the ideal scenario would be a treatment package that prevents relapse when the medication eventually stops. Whether intensive lifestyle work during the treatment window can lock in enough metabolic improvement to hold gains afterward is one of the more important open questions in this space.